Pharmaceuticals company Mankind Pharma announced Q2FY27 results Consolidated Financial Highlights: Revenue from operations stood at Rs 4,337.86 crore for Q2FY27, showing a QoQ growth of 7.62% from Rs 4,030.59 crore in June 30, 2026 (Q1FY27) and a YoY growth of 17.33% compared to Rs 3,697.16 crore in September 30, 2025 (Q2FY26). For H1FY27, consolidated revenue from operations reached Rs 8,368.45 crore, gaining 15.15% YoY against Rs 7,267.51 crore in H1FY26. Total income reached Rs 4,432.71 crore for Q2FY27, increasing by 8.76% QoQ from Rs 4,075.59 crore in Q1FY27 and rising by 16.99% YoY from Rs 3,789.03 crore in Q2FY26. For H1FY27, consolidated total income registered at Rs 8,508.30 crore, a 14.37% YoY surge against Rs 7,439.26 crore in H1FY26. Profit before tax (PBT) arrived at Rs 929.11 crore for Q2FY27, demonstrating a QoQ increase of 20.75% over Rs 769.45 crore in Q1FY27 and a YoY growth of 48.89% against Rs 624.02 crore in Q2FY26. For H1FY27, consolidated PBT recorded at Rs 1,698.56 crore, a 45.86% YoY surge compared to Rs 1,164.51 crore in H1FY26. Profit after tax (PAT) was reported at Rs 716.12 crore for Q2FY27, expanding sequentially by 24.74% from Rs 574.09 crore in Q1FY27 and growing by 37.67% YoY over Rs 520.18 crore in Q2FY26. For H1FY27, consolidated PAT turned out to be Rs 1,290.21 crore, representing a 33.43% YoY rise compared to Rs 964.80 crore in H1FY26. Earnings per equity share (EPS) for basic equity elements stood at Rs 17.23 for Q2FY27, growing sequentially from Rs 13.76 in Q1FY27 and up YoY from Rs 12.39 in Q2FY26. For H1FY27, basic consolidated EPS arrived at Rs 30.99, registering a 34.68% YoY increase against Rs 23.01 in H1FY26. Diluted consolidated EPS stood at Rs 17.20 for Q2FY27, Rs 13.74 for Q1FY27, and Rs 30.94 for H1FY27. Standalone Financial Highlights: Revenue from operations stood at Rs 3,145.22 crore for Q2FY27, mapping a sequential QoQ rise of 6.11% from Rs 2,964.05 crore in Q1FY27 and a YoY expansion of 19.27% over Rs 2,636.95 crore in Q2FY26. For H1FY27, standalone revenue from operations reached Rs 6,109.27 crore, a 17.34% YoY climb over Rs 5,206.68 crore in H1FY26. Total income reached Rs 3,204.05 crore for Q2FY27, climbing sequentially by 6.87% against Rs 2,998.01 crore in Q1FY27 and growing by 18.03% YoY over Rs 2,714.62 crore in Q2FY26. For H1FY27, standalone total income reached Rs 6,202.06 crore, stepping up by 15.94% YoY against Rs 5,349.56 crore in H1FY26. Profit before tax (PBT) arrived at Rs 783.59 crore for Q2FY27, growing sequentially by 3.57% over Rs 756.57 crore in Q1FY27 and climbing YoY by 49.10% compared to Rs 525.53 crore in Q2FY26. For H1FY27, standalone PBT recorded at Rs 1,540.16 crore, demonstrating a 50.74% YoY uptick from Rs 1,021.70 crore in H1FY26. Profit after tax (PAT) was reported at Rs 581.95 crore for Q2FY27, growing sequentially by 4.20% against Rs 558.49 crore in Q1FY27 and rising YoY by 26.57% from Rs 459.80 crore in Q2FY26. For H1FY27, standalone PAT reached Rs 1,140.44 crore, moving up by 30.33% YoY over Rs 875.07 crore in H1FY26. Earnings per equity share (EPS) for basic elements was recorded at Rs 14.09 for Q2FY27, moving up from Rs 13.53 in Q1FY27 and Rs 11.15 in Q2FY26. For H1FY27, standalone basic EPS reached Rs 27.62, a 30.22% YoY growth compared to Rs 21.21 in H1FY26. Standalone diluted EPS arrived at Rs 14.07 for Q2FY27, Rs 13.51 for Q1FY27, and Rs 27.58 for H1FY27. Business Highlights: Intra-Group Schemes of Amalgamation: Scheme 1: The Board of Directors approved a Scheme of Arrangement for the amalgamation of Prolijune Lifesciences Private Limited (PLPL, paid-up share capital Rs 0.49 crore) and Pavi Buildwell Private Limited (PBPL, paid-up share capital Rs 2.01 crore)—both wholly owned subsidiaries—with and into Mankind Pharma Limited. The Appointed Date is defined as April 01, 2027, and no fresh shares or cash considerations will be issued. Scheme 2: The Board took note of the Scheme of Arrangement for the amalgamation of step-down wholly owned subsidiary Upakarma Ayurveda Private Limited (UAPL, paid-up share capital Rs 1.80 crore) with and into Mankind Consumer Products Private Limited (MCPPL, paid-up share capital Rs 129.24 crore). Rajeev Juneja, Vice Chairman & Managing Director, said: Revenue grew ~17% YoY with EBITDA margins improving by 210 bps to 27.1% Strong domestic business growth of 15.9% led by 1.2x volume outperformance to IPM, further supported by: Mid-teen growth in Mankind Domestic with 1.1x Chronic outperformance, led by growth of 19% in Cardiac and 16% in Anti-diabetes. Acute outperformance of 1.1x, led by 19% growth in Gastro and 26% in VMN. Steady double-digit growth in BSV domestic specialty business. International business grew 33%, while OTC witnessed muted growth in Q2. Our disciplined execution and strengthening business fundamentals resulted in strong performance. Our recent acquisition of Armed Cell Therapeutics marks a strategic entry into Next-Generation CAR-T therapies, strengthening R&D; capabilities for future growth. Result PDF